Star-spangled July savings on these new brand and generic Canadian products!

  • Ticagrelor (generic for Brilinta) 

What is ticagrelor? 

Ticagrelor is a generic prescription medication used to prevent blood clots in individuals with acute coronary syndromes, such as unstable angina or heart attacks. It is classified as a platelet aggregation inhibitor and works by inhibiting platelet activation and clot formation in the blood vessels. 

Ticagrelor is typically taken orally in tablet form and is often prescribed in combination with aspirin for antiplatelet therapy. It helps reduce the risk of cardiovascular events by preventing the formation of blood clots that could lead to heart attacks or strokes. 

Manufacturer 

Brilinta (ticagreloris manufactured by AstraZeneca Pharmaceuticals. 

Different strengths of ticagrelor 

Ticagrelor is available in generic form as an oral tablet with strengths of 60 mg and 90 mg. 

Does it have a brand name? 

Yes, the brand name variant of ticagrelor is Brilinta. A kind reminder that generic medications are often more affordable than brand-name medications and contain the same active ingredients and effectiveness. 

Dosage and administration  

Acute Coronary Syndrome (ACS) or a History of Myocardial Infarction  

  • In the management of ACS, initiate ticagrelor tablets treatment with a 180 mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year, administer 60 mg twice daily. 

  • Administer with a daily maintenance dose of aspirin 75 mg to 100 mg 

Coronary Artery Disease but No Prior Stroke or Myocardial Infarction  

  • Administer 60 mg twice daily. For all patients with ACS administer ticagrelor tablets with a daily maintenance dose of aspirin of 75 mg to 100 mg. 

  • patient who misses a dose of ticagrelor tablets should take one tablet (their next dose) at its scheduled time.  

  • For patients who are unable to swallow tablets whole, ticagrelor tablets can be crushed, mixed with water and drunk.  

  • The mixture can also be administered via a nasogastric tube (CH8 or greater) [see Clinical Pharmacology.  

  • Do not administer ticagrelor tablets with another oral P2Y12 platelet inhibitor. 

Drug interactions   

Tell your doctor about all your current medicines. Some medications can affect ticagrelor including, but not limited to: 

  • opioid medication 

  • antifungal medicine 

  • tuberculosis medicine 

  • heart or blood pressure medication 

  • antiviral medicine to treat HIV or AIDS 

  • a blood thinner 

  • cholesterol medication 

  • seizure medicine 

How does ticagrelor work? 

Ticagrelor, a platelet inhibitor, works by preventing platelets from clumping together and forming clots. By inhibiting this process, it helps lower the risk of cardiovascular events by reducing the likelihood of artery blockages and subsequent heart problems. 

  • Qulipta (atogepant)

What is Qulipta? 

Qulipta (atogepant) is a prescription medication used in adults to help prevent migraine headache (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light).  

Atogepant is a small molecule that blocks the binding of Calcitonin gene-related peptide or CGRP to its receptor. CGRP is released from specific parts of the brain and nervous system and may play a role in migraine attacks.   

Manufacturer 

Qulipta is manufactured by AbbVie 

Different strengths of Qulipta 

Qulipta (atogepant) is available as tablets for oral administration containing 10 mg, 30 mg, or 60 mg atogepant. 

Dosage and administration 

  • Qulipta (atogepant) is taken orally with or without food. 

  • For episodic migraine prophylaxis the recommended dosage is 10 mg, 30 mg, or 60 mg taken once daily.  

  • For chronic migraine prophylaxis, the recommended dosage is 60 mg taken once daily. 

Severe Renal Impairment or End-Stage Renal Disease  

  • Episodic migraine: 10 mg once daily.  

  • Chronic migraine: Avoid use.  

  • Other dosage modifications may be required based on other medications and possible drug interactions.

Drug interactions  

Tell your doctor about all your current medicines. Some medications can affect atogepant including, but not limited to: 

  • seizure medicine such as carbamazepine or phenytoin 

  • antiviral medicine to treat HIV, such as efavirenz or etravirine 

  • St. John’s wort 

  • antibiotic such as clarithromycin or rifampin 

  • cyclosporine 

  • antifungal medicine such as itraconazole or ketoconazole 

Can I cut Qulipta in half? 

Qulipta tablets are meant to be swallowed whole. It is not indicated by the manufacturer if the tablets can be crushed, split or chewed. It is generally not recommended to cut or split Qulipta tablets in half unless instructed to do so by a healthcare provider or pharmacist.

  • SOTYKTU (deucravacitinib)

 

What is Sotyktu? 

Sotyktu (deucravacitinib) is a selective immunosuppressant and is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 

Sotyktu works by blocking Tyrosine kinase 2 “TYK2”, which is a type of protein that is involved in inflammation seen in psoriasis.  The active ingredient, deucravacitinib, helps clear skin and reduce psoriasis symptoms such as itching, painfulness, stinging, skin tightness and burning. 

Manufacturer 

Sotyktu is manufactured by Bristol Myers Squibb. 

Different strengths of Sotyktu 

Sotyktu is only available in 6mg tablets. 

Does Sotyktu cause weight loss? 

No, weight loss isn’t a reported side effect of Sotyktu. Although we have a wide range of weight loss products such as OzempicWegovy and Rybelsus. 

Dosage and administration 

  • Recommended dosage is 6 mg orally once daily, with or without food.   

  •  Evaluate patients for active and latent tuberculosis (TB) infection before starting treatment with SOTYKTU.  

  • If positive, start treatment for TB prior to SOTYKTU use  

  • Before starting SOTYKTU you should also discuss with your doctor any infection that doesn’t go away or one that often comes back. SOTYKTU may make you more susceptible to infections and may worsen active infections. 

  • Do not crush, cut, or chew the tablets.  

  • SOTYKTU is not recommended in patients with severe hepatic impairment (Child-Pugh C) No dosage adjustment is needed for patients with mild to moderate hepatic impairment. 

Drug interactions   

  • Tell your doctor about all your current medicines. Some medications can affect deucravacitinib, such as potent immunosuppressants and live vaccines.

For inquiries about prescription medications, contact our team at Jason’s CanadaDrugstore.comby calling 1-800-226 3784 (CAN-DRUG) for assistance from our patient representatives or a licensed Canadian pharmacist.

This article provides medical information to help understand a condition or treatment plan but is not a diagnosis or treatment recommendation. Contact your doctor if you have concerns or symptoms. In case of emergency, call 911.

Be the first to comment

Leave a Reply

Your email address will not be published.


*